Research output: Contribution to journal › Article › peer-review
Safety and Antitumor Activity of the Usnic Acid Derivative OL9-116, a TDP1 Inhibitor, as an Adjunctive Therapy in Combination with Topotecan. / Kornienko, Tatyana E.; Zakharenko, Alexandra L.; Chernyshova, Irina A. et al.
In: International Journal of Molecular Sciences, Vol. 27, No. 20, 9266, 19.10.2026.Research output: Contribution to journal › Article › peer-review
}
TY - JOUR
T1 - Safety and Antitumor Activity of the Usnic Acid Derivative OL9-116, a TDP1 Inhibitor, as an Adjunctive Therapy in Combination with Topotecan
AU - Kornienko, Tatyana E.
AU - Zakharenko, Alexandra L.
AU - Chernyshova, Irina A.
AU - Chepanova, Arina A.
AU - Dyrkheeva, Nadezhda S.
AU - Firsova, Alina A.
AU - Rogachev, Artem D.
AU - Luzina, Olga A.
AU - Popova, Nelly A.
AU - Maksimova, Varvara P.
AU - Vlasova, Olga A.
AU - Deryagina, Valentina P.
AU - Rodnyy, Alexander Ya.
AU - Salakhutdinov, Nariman F.
AU - Lavrik, Olga I.
N1 - Kornienko, T.E.; Zakharenko, A.L.; Chernyshova, I.A.; Chepanova, A.A.; Dyrkheeva, N.S.; Firsova, A.A.; Rogachev, A.D.; Luzina, O.A.; Popova, N.A.; Maksimova, V.P.; et al. Safety and Antitumor Activity of the Usnic Acid Derivative OL9-116, a TDP1 Inhibitor, as an Adjunctive Therapy in Combination with Topotecan. Int. J. Mol. Sci. 2026, 27, 9266. https://doi.org/10.3390/ijms27209266 This study was funded by Russian Science Foundation (grant no. 25-24-00247).
PY - 2026/10/19
Y1 - 2026/10/19
N2 - Topotecan inhibits topoisomerase 1 (TOP1) by trapping the enzyme in a DNA-cleavage complex, which can be repaired by tyrosyl-DNA phosphodiesterase 1 (TDP1). The usnic acid derivative OL9-116 inhibits TDP1 and thereby enhances the antitumor activity of topotecan, making it a promising combination partner. However, the safety and optimal administration schedule of OL9-116 with topotecan have not been characterized. We demonstrated that OL9-116 has no genotoxic or epigenetic effects using Ames and CBMN assays, as well as HeLa trichostatin A-inducible cells with an epigenetically repressed GFP gene. Intraperitoneal administration was found to provide higher bioavailability than intragastric administration. We showed on the RShM-5 cervical cancer model that repeated topotecan administration in a clinically relevant low single-dose regimen was more effective than a single injection, and addition of topotecan at the Tmax of OL9-116 enhanced tumor growth inhibition. In the Lewis lung carcinoma model, the OL9-116–topotecan combination reduced primary tumor mass and lung metastases, enhancing both antitumor and antimetastatic effects. Monitoring of hematological parameters, liver, and spleen indices revealed no clinically significant toxicity. Moreover, peripheral blood parameters improved with the OL9-116–topotecan combination compared with topotecan monotherapy. Collectively, these findings support OL9-116 as a promising safe TDP1 inhibitor for combination with topotecan.
AB - Topotecan inhibits topoisomerase 1 (TOP1) by trapping the enzyme in a DNA-cleavage complex, which can be repaired by tyrosyl-DNA phosphodiesterase 1 (TDP1). The usnic acid derivative OL9-116 inhibits TDP1 and thereby enhances the antitumor activity of topotecan, making it a promising combination partner. However, the safety and optimal administration schedule of OL9-116 with topotecan have not been characterized. We demonstrated that OL9-116 has no genotoxic or epigenetic effects using Ames and CBMN assays, as well as HeLa trichostatin A-inducible cells with an epigenetically repressed GFP gene. Intraperitoneal administration was found to provide higher bioavailability than intragastric administration. We showed on the RShM-5 cervical cancer model that repeated topotecan administration in a clinically relevant low single-dose regimen was more effective than a single injection, and addition of topotecan at the Tmax of OL9-116 enhanced tumor growth inhibition. In the Lewis lung carcinoma model, the OL9-116–topotecan combination reduced primary tumor mass and lung metastases, enhancing both antitumor and antimetastatic effects. Monitoring of hematological parameters, liver, and spleen indices revealed no clinically significant toxicity. Moreover, peripheral blood parameters improved with the OL9-116–topotecan combination compared with topotecan monotherapy. Collectively, these findings support OL9-116 as a promising safe TDP1 inhibitor for combination with topotecan.
KW - Ингибиторы TDP1
KW - топотекан
KW - комбинированная химиотерапия
KW - тест Эймса
KW - микроядерный тест с блокированием цитокинеза (CBMN-тест)
KW - эпигенетические эффекты
KW - фармакокинетика
KW - карцинома легкого Льюис (LLC)
KW - рак шейки матки (RShM-5)
UR - https://www.mendeley.com/catalogue/373e88df-3b6e-3d58-be67-68e69e5dda29/
UR - https://www.scopus.com/pages/publications/105055019077
U2 - 10.3390/ijms27209266
DO - 10.3390/ijms27209266
M3 - Article
C2 - 42942035
VL - 27
JO - International Journal of Molecular Sciences
JF - International Journal of Molecular Sciences
SN - 1661-6596
IS - 20
M1 - 9266
ER -
ID: 85471778